NME4 is highly expressed in ccRCC, and its expression levels are significantly associated with patients' clinical characteristics and survival prognosis. Meanwhile, experimental results indicate its important role in tumorigenesis and progression. NME4 has the potential to serve as a biomarker and therapeutic target for ccRCC.
Cheng et al. (Thu,) studied this question.